Trial of PTK787/ZK 222584 Plus Paclitaxel
NCT00358163
Terminated
PTK787/ZK 222584 is an inhibitor of VEGFR family tyrosine kinases. The primary objective of this study is to assess the safety of daily oral PTK787/ZK 222584 in combination with paclitaxel infused every 21 days. Secondary objectives include pharmacokinetic assessment of the impact of PTK787/ZK 222584 on paclitaxel metabolism and evaluation of tumor response to the investigational treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2022
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Metastatic Non-hematologic Malignancies
Register for Updates
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
NCT00432094
Completed
RATIONALE: Germ cell tumors (GCT) are highly sensitive to chemotherapy such that even with metastatic disease at diagnosis, many patients can be cured. Patients who fall into the poor risk category or others who relapse can be successfully salvaged with high dose chemotherapy and autologous stem cell transplant (AuSCT). As in other diseases such as myeloma, sequential high dose chemotherapy and AuSCT may improve overall and disease free survival. PURPOSE: Because prior investigations in GCT sug... Read More
Gender:
ALL
Ages:
Between 10 years and 69 years
Trial Updated:
04/22/2022
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota
Conditions: Childhood Germ Cell Tumor, Ovarian Cancer, Teratoma
Register for Updates
LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer
NCT04762901
Withdrawn
This is an open-label, two-stage, multi-arm Phase 1 study designed to evaluate the safety and preliminary efficacy of combining niraparib with four standard chemotherapy regimens used to treat TNBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2022
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Breast Cancer
Register for Updates
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
NCT01547741
Unknown
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/13/2022
Locations: Providence Alaska Medical Center, Anchorage, Alaska +914 locations
Conditions: Breast Cancer
Register for Updates
Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer
NCT02698891
Completed
This research study is testing the safety and feasibility of delivering the 4 cycles of 'dose-dense' paclitaxel without the use of Neulasta (Pegfilgrastim) as a Granulocyte Colony-stimulating Factor (G-CSF) support. The research study is for participants who have early stage breast cancer and have been recommended to receive a standard chemotherapy regimen, doxorubicin/cyclophosphamide (AC) plus Paclitaxel (T), in what is called a "dose-dense" fashion to prevent recurrences.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/11/2022
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +3 locations
Conditions: Early Stage Breast Cancer
Register for Updates
Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts
NCT01643460
Completed
The purpose of this study is to track outcomes and complications of patients at IUMC referred by physicians for EUS-guided pancreatic cyst ablation. This information is essential in order to disseminate future published information to physicians about this technique. A database will be created to track these patients undergoing an already scheduled/planned procedure. Phone calls at selected intervals will be made following the procedure to track any complications that occur
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/06/2022
Locations: Indiana University Hospital, Indianapolis, Indiana
Conditions: Pancreatic Cyst, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Cystadenoma, Mucinous, Papillary Mucinous Cystadenoma, Borderline Malignancy
Register for Updates
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
NCT02711137
Terminated
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with advanced malignancies. Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic activity. Part 2 will further evaluate the safety, preliminary efficacy, PK, and PD of the dose(s) selected in Part 1 i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2022
Locations: University of Alabama, Birmingham, Alabama +17 locations
Conditions: Solid Tumors
Register for Updates
A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer
NCT01506973
Completed
In this Phase I/II clinical trial, the investigators seek to pilot the addition of Hydroxychloroquine (HCQ) to a commonly-used front-line therapy of pancreatic cancer, gemcitabine/nab-paclitaxel. The investigators plan a run-in to define tolerable doses, and will explore doses of 800 and 1200 mg/day in successive cohorts of 6 patients. The investigators will assess toxicity continuously, and determine the dose for the Phase II trial based on standard toxicity criteria. The correlative endpoints... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2022
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Advanced Adenocarcinoma, Metastatic Adenocarcinoma
Register for Updates
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
NCT02824575
Terminated
The purpose of this study is to determine the safety and tolerability of rebastinib when combined with antitubulin therapy with paclitaxel or eribulin in patients with advanced breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/23/2022
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Breast Cancer, Breast Adenocarcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Register for Updates
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
NCT01721746
Completed
The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/23/2022
Locations: Mayo Clinic, Phoenix, Arizona +94 locations
Conditions: Unresectable or Metastatic Melanoma
Register for Updates
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
NCT02367794
Completed
This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2022
Locations: Ironwood Cancer & Research Centers, Chandler, Arizona +241 locations
Conditions: Squamous Non-Small Cell Lung Cancer
Register for Updates
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
NCT03770299
Withdrawn
The purpose of this study is to determine if nivolumab added to the standard of care therapy (SOC) given after surgery is more effective than SOC alone in prolonging disease free survival in NSCLC participants with minimal residual disease detected after surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/09/2022
Locations: Local Institution, Jacksonville, Florida +12 locations
Conditions: Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Circulating Tumor DNA
Register for Updates